LOS ANGELES (Reuters) - Continued use of Rituxan cut by about 50 percent the risk that follicular lymphoma patients would have their cancer return, according to a late-stage study of the drug, which ...
Imbruvica plus Rituxan significantly improved PFS and response rates in Waldenstrom’s macroglobulinemia patients compared to placebo plus Rituxan. The combination therapy showed a 68% PFS rate at 54 ...
Roche Holding AG’s RHHBY member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris. Rituxan is ...
“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an ...
SOUTH SAN FRANCISCO, Calif. & WESTON, Mass.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and ...
The Food and Drug Administration has approved the first biosimilar version of a drug commonly used to treat the most widespread forms of lymphoma. The agency said Wednesday that it had approved ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of Celltrion is seen at company's headquarters in Incheon, South Korea, October 28, 2016. REUTERS/Kim Hong-Ji ...
A trial of Roche Holding's <ROG.VX Rituxan found that use of the drug in patients with a type of slow-growing lymphoma significantly delayed the need for chemotherapy treatment. The typical practice ...
Roche’s Rituxan (rituximab) has been on the market for years as a blood cancer drug, and is finally succumbing to pressure from cut-price biosimilars. But the company’s Genentech unit has new data ...
The blockbuster cancer drug Rituxan may help treat multiple sclerosis, according to the results of a small clinical trial that opens up a broad new approach to understanding and possibly treating the ...
(Recasts, adds researcher quotes) By Ransdell Pierson NEW YORK, May 1 (Reuters) - Genentech Inc. <DNA.N> and Biogen Idec Inc. <BIIB.O> said on Tuesday their Rituxan cancer drug proved highly effective ...
SOUTH SAN FRANCISCO, Calif. & WESTON, Mass.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results